Refine Search

New Search

Results: 24

(searched for: doi:10.3816/clml.2011.n.005)
Save to Scifeed
Page of 1
Articles per Page
by
Show export options
  Select all
Asaad Azarnezhad, , Mehdi Jaymand, Mahsa Sobhani,
Critical Reviews in Toxicology, Volume 50, pp 148-176; doi:10.1080/10408444.2020.1719974

The publisher has not yet granted permission to display this abstract.
Tiffany Li, Hannah C. Timmins, Tracy King, Matthew C. Kiernan, David Goldstein,
Published: 24 December 2019
by Wiley
Hematological Oncology, Volume 38, pp 229-243; doi:10.1002/hon.2706

The publisher has not yet granted permission to display this abstract.
Marjan Abri Aghdam, Roya Bagheri, Jafar Mosafer, , Mahmoud Hashemzaei, , ,
Published: 10 December 2019
Journal of Controlled Release, Volume 315, pp 1-22; doi:10.1016/j.jconrel.2019.09.018

The publisher has not yet granted permission to display this abstract.
Biomaterials Research, Volume 23, pp 1-29; doi:10.1186/s40824-019-0166-x

Abstract:
In modern-day medicine, nanotechnology and nanoparticles are some of the indispensable tools in disease monitoring and therapy. The term “nanomaterials” describes materials with nanoscale dimensions (< 100 nm) and are broadly classified into natural and synthetic nanomaterials. However, “engineered” nanomaterials have received significant attention due to their versatility. Although enormous strides have been made in research and development in the field of nanotechnology, it is often confusing for beginners to make an informed choice regarding the nanocarrier system and its potential applications. Hence, in this review, we have endeavored to briefly explain the most commonly used nanomaterials, their core properties and how surface functionalization would facilitate competent delivery of drugs or therapeutic molecules. Similarly, the suitability of carbon-based nanomaterials like CNT and QD has been discussed for targeted drug delivery and siRNA therapy. One of the biggest challenges in the formulation of drug delivery systems is fulfilling targeted/specific drug delivery, controlling drug release and preventing opsonization. Thus, a different mechanism of drug targeting, the role of suitable drug-laden nanocarrier fabrication and methods to augment drug solubility and bioavailability are discussed. Additionally, different routes of nanocarrier administration are discussed to provide greater understanding of the biological and other barriers and their impact on drug transport. The overall aim of this article is to facilitate straightforward perception of nanocarrier design, routes of various nanoparticle administration and the challenges associated with each drug delivery method.
Vivek K Chaturvedi, Anshuman Singh, Vinay K. Singh,
Current Drug Metabolism, Volume 20, pp 416-429; doi:10.2174/1389200219666180918111528

The publisher has not yet granted permission to display this abstract.
文曹 怡, 施 晴, 晨张 慕, 鹏许 彭, 程 澍, 莅赵 维, 王 黎, Y W Cao, Q Shi, M C Zhang, et al.
Published: 14 June 2018
Zhonghua Xue Ye Xue Za Zhi, Volume 39, pp 485-490

Abstract:
评估RCDOP(利妥昔单抗、环磷酰胺、脂质体多柔比星、长春新碱、泼尼松)方案在弥漫大B细胞淋巴瘤(DLBCL)患者中的疗效。 回顾性分析2012年10月至2017年10月应用RCDOP方案治疗的87例初治DLBCL患者资料,结合临床特征进行疗效和生存分析。 ①87例患者中,男40例,女47例,中位年龄60(14~84)岁。应用RCDOP方案治疗后,获得完全缓解(CR)和部分缓解(PR)者共计81例(93.10%)。②根据IPI评分不同危险度分层(低、中、高危)、结外累及部位(0~1个/≥2个)、肿块大小(<7.5 cm≥7.5 cm)、年龄(≤60岁/>60岁)、LDH(正常/升高)、Ann Arbor分期(Ⅰ~Ⅱ期/Ⅲ~Ⅳ期)、Ki-67阳性率(>80%/≤80%)对患者进行分组,比较组间无进展生存(PFS)和总生存(OS)的差异。结果显示,RCDOP方案治疗后,中位随访时间为9个月,IPI评分低、中、高危三组患者的1年PFS率(P=0.084)和OS率(P=0.515)差异无统计学意义,其余组间比较患者的1年PFS率和OS率差异也均无统计学意义(P值均>0.05)。 RCDOP方案可以改善IPI评分中高危、结外多部位累及、巨大肿块、年龄>60岁、高LDH、Ann Arbor分期Ⅲ~Ⅳ期和Ki-67阳性率>80%患者的早期疗效。
Deepak Solomon, Nilesh Gupta, Nihal S. Mulla, Snehal Shukla, Yadir A. Guerrero,
The AAPS Journal, Volume 19, pp 1669-1681; doi:10.1208/s12248-017-0142-0

The publisher has not yet granted permission to display this abstract.
建刘 文, 达王 维, 王 华, 华王 惊, 吕 跃, W J Liu, W D Wang, H Wang, J H Wang, Y Lyu
Published: 14 June 2017
Zhonghua Xue Ye Xue Za Zhi, Volume 38, pp 542-544

Yannan Dou, Kullervo Hynynen,
Published: 1 March 2017
Journal of Controlled Release, Volume 249, pp 63-73; doi:10.1016/j.jconrel.2017.01.025

The publisher has not yet granted permission to display this abstract.
Qi Wang,
The Journal of Biomedical Research, Volume 32, pp 91-106; doi:10.7555/JBR.31.20160146

Abstract:
Incorporating both diagnostic and therapeutic functions into a single nanoscale system is an effective modern drug delivery strategy. Combining liposomes with semiconductor quantum dots (QDs) has great potential to achieve such dual functions, referred to in this review as a liposomal QD hybrid system (L-QD). Here we review the recent literature dealing with the design and application of L-QD for advances in bio-imaging and drug delivery. After a summary of L-QD synthesis processes and evaluation of their properties, we will focus on their multifunctional applications, ranging from in vitro cell imaging to theranostic drug delivery approaches.
Mangal Shailesh Nagarsenker, Megha Sunil Marwah
Machine Learning in Cancer Research With Applications in Colon Cancer and Big Data Analysis pp 52-87; doi:10.4018/978-1-5225-0751-2.ch003

The publisher has not yet granted permission to display this abstract.
Jonathan D. Ashley, Charissa J. Quinlan, Valerie A. Schroeder, Mark A. Suckow, Vincenzo J. Pizzuti, ,
Molecular Cancer Therapeutics, Volume 15, pp 1452-1459; doi:10.1158/1535-7163.mct-15-0867

Abstract:
Here, we report the synthesis and evaluation of dual drug–loaded nanoparticles as an effective means to deliver carfilzomib and doxorubicin to multiple myeloma tumor cells at their optimal synergistic ratio. First, various molar ratios of carfilzomib to doxorubicin were screened against multiple myeloma cell lines to determine the molar ratio that elicited the greatest synergy using the Chou–Talalay method. The therapeutic agents were then incorporated into liposomes at the optimal synergistic ratio of 1:1 to yield dual drug–loaded nanoparticles with a narrow size range of 115 nm and high reproducibility. Our results demonstrated that the dual drug–loaded liposomes exhibited synergy in vitro and were more efficacious in inhibiting tumor growth in vivo than a combination of free drugs, while at the same time reducing systemic toxicity. Taken together, this study presents the synthesis and preclinical evaluation of dual drug–loaded liposomes containing carfilzomib and doxorubicin for enhanced therapeutic efficacy to improve patient outcome in multiple myeloma. Mol Cancer Ther; 15(7); 1452–9. ©2016 AACR.
Himanshu Pandey, Radha Rani,
Brazilian Archives of Biology and Technology, Volume 59; doi:10.1590/1678-4324-2016150477

Abstract:
Liposomes, the vesicles of phospholipid bilayer, can encapsulate both hydrophilic and lipophilic drugs and protect them from degradation. Liposomes have been extensively studied and continue to create intense interest in research since their discovery in the mid-1960s. Since then, liposomes have been considered to be the most successful nanocarriers for drug deliver and have made their way to the market. Currently, a number of liposomal formulations are on the marker for cancer treatment and many more are in pipe line. This review discusses about the liposome components, methods of preparation, drug encapsulation mechanism and the potential therapeutic applications of liposomes in cancer therapy.
, Pieter Sonneveld
Expert Opinion on Pharmacotherapy, Volume 16, pp 1945-1957; doi:10.1517/14656566.2015.1075507

The publisher has not yet granted permission to display this abstract.
Indian Journal of Hematology and Blood Transfusion, Volume 32, pp 3-9; doi:10.1007/s12288-015-0575-5

Abstract:
Multiple myeloma (MM) is a heterogeneous disease with varied outcome. The novel agents including two major classes of drugs; the immunomodulatory drugs and the proteasome inhibitors with unprecedented response rates, have replaced conventional chemotherapy. With monoclonal antibodies on the horizon, outcome of this disorder will further improve. Progression in risk stratification systems has made it possible to predict the disease course as well as outcome in myeloma patients with disease categorization into low to high risk. In addition, detection of minimal residual disease by serum free light chain assay, flow cytometry, molecular techniques like polymerase chain reaction and positron emission tomography scan is playing an important role in modifying the treatment. An extensive research in the disease biology has improved our knowledge regarding interplay between myeloma cells and elements of the bone marrow microenvironment which contribute to sustain proliferation and survival as well as de novo drug resistance. Again, insight into the role of genetic and epigenetic interactions in MM has exposed new molecular targets. All these have opened the gateway for novel therapeutic strategies with focus on risk based individualized therapy.
Jonathan D. Ashley, Jared F. Stefanick, Valerie A. Schroeder, Mark A. Suckow, , Rikio Suzuki, Shohei Kikuchi, , Kenneth C. Anderson, , et al.
Published: 1 December 2014
Journal of Controlled Release, Volume 196, pp 113-121; doi:10.1016/j.jconrel.2014.10.005

The publisher has not yet granted permission to display this abstract.
Giuseppe Visani, Federica Loscocco,
Published: 1 October 2014
Nanomedicine, Volume 9, pp 2415-2428; doi:10.2217/nnm.14.128

The publisher has not yet granted permission to display this abstract.
Pritesh Jain, Gerd Leitinger, Regina Leber, Chandran Nagaraj, Bernhard Lehofer, , Andrea Olschewski, ,
International Journal of Nanomedicine, Volume 9, pp 3249-61; doi:10.2147/ijn.s63190

Abstract:
Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries Pritesh P Jain,1 Regina Leber,1,2 Chandran Nagaraj,1 Gerd Leitinger,3 Bernhard Lehofer,4 Horst Olschewski,1,5 Andrea Olschewski,1,6 Ruth Prassl,1,4 Leigh M Marsh11Ludwig Boltzmann Institute for Lung Vascular Research, 2Biophysics Division, Institute of Molecular Biosciences, University of Graz, 3Research Unit Electron Microscopic Techniques, Institute of Cell Biology, Histology, and Embryology, 4Institute of Biophysics, 5Division of Pulmonology, Department of Internal Medicine, 6Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria Prostacyclin analogues are standard therapeutic options for vasoconstrictive diseases, including pulmonary hypertension and Raynaud’s phenomenon. Although effective, these treatment strategies are expensive and have several side effects. To improve drug efficiency, we tested liposomal nanoparticles as carrier systems. In this study, we synthesized liposomal nanoparticles tailored for the prostacyclin analogue iloprost and evaluated their pharmacologic efficacy on mouse intrapulmonary arteries, using a wire myograph. The use of cationic lipids, stearylamine, or 1,2-di-(9Z-octadecenoyl)-3-trimethylammonium-propane (DOTAP) in liposomes promoted iloprost encapsulation to at least 50%. The addition of cholesterol modestly reduced iloprost encapsulation. The liposomal nanoparticle formulations were tested for toxicity and pharmacologic efficacy in vivo and ex vivo, respectively. The liposomes did not affect the viability of human pulmonary artery smooth muscle cells. Compared with an equivalent concentration of free iloprost, four out of the six polymer-coated liposomal formulations exhibited significantly enhanced vasodilation of mouse pulmonary arteries. Iloprost that was encapsulated in liposomes containing the polymer polyethylene glycol exhibited concentration-dependent relaxation of arteries. Strikingly, half the concentration of iloprost in liposomes elicited similar pharmacologic efficacy as nonencapsulated iloprost. Cationic liposomes can encapsulate iloprost with high efficacy and can serve as potential iloprost carriers to improve its therapeutic efficacy.Keywords: prostacyclin, cationic liposomes, pulmonary hypertension, wire myograph
, Annalisa Chiarenza, Concetta Conticello, Maide Cavalli, Calogero Vetro, , Rosario Cunsolo, ,
Published: 18 April 2014
by Wiley
European Journal of Haematology, Volume 93, pp 207-213; doi:10.1111/ejh.12325

The publisher has not yet granted permission to display this abstract.
, T. M. Allen, P. R. Cullis
Drug Delivery and Translational Research, Volume 4, pp 74-83; doi:10.1007/s13346-013-0161-z

The publisher has not yet granted permission to display this abstract.
, Pieter R. Cullis
Published: 1 January 2013
Advanced Drug Delivery Reviews, Volume 65, pp 36-48; doi:10.1016/j.addr.2012.09.037

The publisher has not yet granted permission to display this abstract.
Monika Garg, , Ravi Shankar Pandey, Satish Sardana, , Ramesh Chandra
Anti-Cancer Drugs, Volume 23, pp 836-845; doi:10.1097/cad.0b013e328351424f

The publisher has not yet granted permission to display this abstract.
, Gillian M. Keating
Published: 1 December 2011
Drugs, Volume 71, pp 2531-2558; doi:10.2165/11207510-000000000-00000

The publisher has not yet granted permission to display this abstract.
Page of 1
Articles per Page
by
Show export options
  Select all
Back to Top Top